METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
|Articles|October 28, 2015
Valeant Responds to Drug Distribution Criticisms
Author(s)Randi Hernandez
October 28, 2015.
Advertisement
According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the
BioPharm International's Randi Hernandez reports on
Advertisement
Related to this article
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
2
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
3
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
4
Pharmaceutical Executive Daily: FDA Approves Hibsago
5